Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CYorf17
REST API REST API
Homo sapiens
CYorf17 is differentially expressed in 118 experiments: 75 organism parts: lung, heart, ... (73 more);, 107 disease states: normal, Emery-Dreifuss muscular dystrophy, ... (105 more);, 37 cell types 71 cell lines 12 compound treatments and 59 other conditions.
InterPro Term DUF1725
UniProt Accession Q9H606
Search EB-eye ENSG00000183146
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-MTAB-24, E-MTAB-25, E-TABM-145, ... (16 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-22639, E-GEOD-18005, ... (16 experiments)

Factor Value U/D Experiments
PC3
1
E-MEXP-2034
NCIH716
1
E-MTAB-37
MDA231
1
E-GEOD-20089
SUDHL10
1
E-MTAB-37
A459
1
E-GEOD-17347
DOHH2
1
E-MTAB-37
65 more value(s).


Cell type

studied in E-GEOD-10797, E-GEOD-18811, E-AFMX-5, E-GEOD-3920, E-TABM-130, ... (21 experiments)

Factor Value U/D Experiments
stromal cell
1
2
E-GEOD-10797, E-MEXP-2034, E-GEOD-1460
centroblast
1
E-TABM-702
PBMCs
1
E-GEOD-20677
lung carcinoma
1
E-GEOD-17347
erythropoietic
1
E-GEOD-9894
granulocyte
1
E-MEXP-583
31 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-1869, E-GEOD-1577, E-GEOD-20602, ... (27 experiments)

Factor Value U/D Experiments
control
2
E-GEOD-20602, E-GEOD-20168
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
prostate carcinoma
1
E-MEXP-2034
hereditary leiomyomatosis and renal cell cancer
1
E-MTAB-62
neuroblastoma
1
E-MTAB-62
oligodendroglioma
1
E-GEOD-4290
101 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-3284, E-TABM-127, E-GEOD-5824, E-GEOD-7307, ... (7 experiments)

Factor Value U/D Experiments
cigarette smoke
1
1
E-TABM-127
bacterial endotoxin
1
1
E-GEOD-3284
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
no estradiol
1
E-GEOD-20081
not specified
1
E-GEOD-20081
SDF + Cxcr4
1
E-GEOD-7307
6 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-21374

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-4667, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743

Environmental stress
studied in E-GEOD-1643

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578

Genotype
studied in E-GEOD-17476, E-GEOD-17347

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-TABM-127

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-666, E-MEXP-1648, E-GEOD-19519, ... (14 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-21837, E-GEOD-19246

RNAi
studied in E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Processing time: 0.478 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM